Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 16/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 16/20 | 0.74 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.74 |
| ▸ | NSD2 | O96028 | 1/20 | 0.74 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.74 |
| ▸ | POLB | P06746 | 11/20 | 0.72 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.72 |
| ▸ | BLM | P54132 | 2/20 | 0.70 |
| ▸ | ATM | Q13315 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.67 |
| ▸ | CASP3 | P42574 | 2/20 | 0.59 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.59 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.59 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | GALK1 | P51570 | 1/20 | 0.59 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.58 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205465 | 0.87 | PDE4B (0.62) | MEN1KMT2AHSP90AA1NSD2APOBEC3G | |
| SCHEMBL19999128 | 0.87 | PDE4B (0.62) | MEN1KMT2AHSP90AA1NSD2APOBEC3G | |
| SCHEMBL8205466 | 0.87 | PDE4B (0.62) | MEN1KMT2AHSP90AA1NSD2APOBEC3G | |
| SCHEMBL18102989 | 0.86 | CTNNB1 (0.65) | MEN1KMT2APOLBL3MBTL1USP2 | |
| SCHEMBL18095863 | 0.86 | CTNNB1 (0.65) | MEN1KMT2APOLBL3MBTL1USP2 | |
| SCHEMBL18095861 | 0.86 | CTNNB1 (0.65) | MEN1KMT2APOLBL3MBTL1USP2 | |
| SCHEMBL19999129 | 0.86 | CTNNB1 (0.64) | MEN1KMT2AHSP90AA1NSD2APOBEC3G | |
| SCHEMBL18103012 | 0.85 | MEN1 (1.00) | MEN1KMT2AHSP90AA1NSD2APOBEC3G | |
| SCHEMBL12008777 | 0.84 | CTNNB1 (0.81) | MEN1KMT2APOLBCTNNB1TCF7L2 | |
| SCHEMBL19999126 | 0.84 | CTNNB1 (0.57) | MEN1KMT2AHSP90AA1NSD2APOBEC3G |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | UNIVERSITY OF MIAMI (US) | 2019-12-10 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10501413-B2 | Inhibitors of the Notch transcriptional activation complex and methods for use of the same | NOTCH1, CBFB, HES1 | MEN1 846/4885KMT2A 470/4885HSP90AA1 4481/4885 |
| US-20180086700-A1 | INHIBITORS OF THE NOTCH TRANSCRIPTIONAL ACTIVATION COMPLEX AND METHODS FOR USE OF THE SAME | NOTCH1, CBFB, HES1 | MEN1 846/4885KMT2A 470/4885HSP90AA1 4481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.